Future oncology
-
Review Meta Analysis
Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis.
We performed a meta-analysis of the risk of endocrine adverse events associated with immune check point inhibitors. ⋯ Our meta-analysis has demonstrated that the use of immune check point inhibitors is associated with an increased risk of hypothyroidism, hyperthyroidism, hypophysitis and adrenal insufficiency compared with control.
-
38th San Antonio Breast Cancer Symposium, San Antonio, TX, USA, 8-12 December 2015. In November 1978, during Breast Cancer Awareness Week, the first annual San Antonio Breast Cancer Symposium (SABCS) was held as a part of an educational program conceived to reduce breast cancer death rate. ⋯ Recently, the 38th edition of the SABCS welcomed >7000 attendees from all over the world. We will discuss a selection of the most significant advances presented at the 2015 SABCS, specifically focusing on those data that could have an impact on the clinical practice in the near future.
-
First-generation reversible EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs) changed our understanding of advanced non-small-cell lung cancer biology and behavior. The presence of sensitizing EGFR mutations in advanced non-small-cell lung cancer defines a subset of patients with a better prognosis and sensitivity to EGFR-TKIs with a better response rate, progression-free survival, quality of life and symptom control than with chemotherapy in the first-line therapy setting. ⋯ Afatinib is an irreversible pan-ErbB-TKI, active against wild-type EGFR, sensitizing and T970M-mutant EGFR, ErbB2 and ErbB4 receptors, and represents a step change between reversible first-generation and future irreversible highly specific third-generation EGFR-TKIs. Here, we review the clinical development of afatinib through the LUX-Lung trials portfolio highlighting benefits and toxicities.